A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia
Phase 1
Withdrawn
- Conditions
- COVID-19
- Interventions
- Other: Vehicle controlDrug: ORTD-1 low doseDrug: ORTD-1 mid doseDrug: ORTD-1 high dose
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Oryn Therapeutics, LLC
- Registration Number
- NCT04708236
- Locations
- ๐บ๐ธ
UC Irvine Medical Center, Orange, California, United States
Randomized, Double-blind, Vehicle Controlled, Repeat Dose Comparative Study in RA Patients Managed With DMARDs
Phase 1
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: Low dose vehicle controlDrug: High dose vehicle controlDrug: Low dose ORTD-1Drug: High dose ORTD-1
- First Posted Date
- 2020-02-27
- Last Posted Date
- 2021-10-19
- Lead Sponsor
- Oryn Therapeutics, LLC
- Target Recruit Count
- 17
- Registration Number
- NCT04286789
- Locations
- ๐บ๐ธ
Keck School of Medicine of USC Division of Rheumatology, Los Angeles, California, United States
๐บ๐ธOrange County Research Center, Tustin, California, United States
๐บ๐ธAdvanced Pharma CR, LLC, Miami, Florida, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath